After being called out on some intellectual property claims late last year, Teva has fallen victim to the Federal Trade Commission’s (FTC’s) ongoing crusade against questionable drug patents.
With the backing of the U.S. Federal Trade Commission, Amneal convinced a New Jersey federal court on Monday to remove five Teva Pharmaceutical patents from a Food and Drug Administration list of ...
The government has a variety of strategies to protect the public from price-gouging and information advantages over the ...
Two prominent congressional Democrats this week wrote to eight pharmaceutical company CEOs, urging them to remove 130 patents ...
Policy differences are endemic in politics, and the phrase "causing more heat than light" regarding federal drug policy comes readily to mind listening to the rhetoric coming from the Federal ...
“There is no dispute that the Inhaler Patents contain no claim for the active ingredient at issue, albuterol sulfate. Amneal contends that the Inhaler Patents do not meet the requirement that ...
Opinions expressed by Forbes Contributors are their own. The narrative around so-called junk fees, as the regulators began contemplating new restrictions, seemed to define the target as extra ...
Nicole Narea covers politics and society for Vox. She first joined Vox in 2019, and her work has also appeared in Politico, Washington Monthly, and the New Republic. President Joe Biden has ...
, opens new tab with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court on Monday to remove five Teva Pharmaceutical (TEVA.TA) , opens new tab patents from a U.S ...
Democrats have hit on a new tactic in their long battle with drug companies: challenge patents that they say are deliberate attempts to game the system and box out low-cost, generic competitors.